Vimta Labs Limited — Updates, 28-04-2025: Press Release

Vimta Labs Limited's Q4 and FY25 results show significant growth, with total income reaching Rs. 961 Mn, marking a 31.4% year-on-year increase. EBITDA was Rs. 347 Mn, yielding a strong margin of 36.1%. The profit after tax (PAT) also rose to Rs. 183 Mn, maintaining a PAT margin of 19.1%. For the full financial year, total income stood at Rs. 3,482 Mn, with a PAT of Rs. 668 Mn, reflecting a 36.8% rise compared to the previous year.

Strategically, Vimta is expanding into Biologics Contract R&D services, targeting novel biologics and peptide therapeutics. This initiative is expected to position the company as a leader in the biopharmaceutical sector, with revenue generation anticipated by FY27. Other notable developments include a successful cGMP audit by EMA and the granting of an Outstanding Laboratory Performance Award in 2024. The company is set for a promising future, enhancing its service offerings while maintaining a strong financial foundation. Investors should monitor these developments closely as they could drive further growth.